Licogliflozin

Legal status

• Investigational

CAS Number

• 1291094-73-9 ^Y

PubChem CID

• 52913524

IUPHAR/BPS

• 10654

Licogliflozin

Legal status
Legal status	Investigational
Identifiers
IUPAC name (2S,3R,4R,5S,6R)-2-{3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-ethylphenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number	1291094-73-9 Y
PubChem CID	52913524
IUPHAR/BPS	10654
DrugBank	DB15048
ChemSpider	71045806
UNII	57J06X6EI0
ChEMBL	ChEMBL4297625
Chemical and physical data
Formula	C23H28O7
Molar mass	416.470 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
InChI InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1 Key:XFJAMQQAAMJFGB-ZQGJOIPISA-N

Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity,^[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.^[2][3]